TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.45
-0.07 (-0.82%)
Apr 28, 2026, 4:00 PM EDT - Market closed
TransCode Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -34.66 | -16.75 | -18.55 | -17.56 | -6.84 | |
| Depreciation & Amortization | 0.11 | 0.53 | 0.52 | 0.1 | 0.04 | |
| Loss (Gain) From Sale of Assets | - | - | - | - | 0 | |
| Stock-Based Compensation | 0.49 | 1.7 | 1.04 | 0.4 | 0.19 | |
| Other Operating Activities | 14.53 | 1.54 | - | - | 0.91 | |
| Change in Accounts Payable | 0.22 | -0.34 | -1.3 | 1.84 | 2.29 | |
| Change in Unearned Revenue | -0.03 | -0 | 0.03 | -0.03 | 0.03 | |
| Change in Other Net Operating Assets | -0.4 | -0.01 | 0.19 | -0.5 | -1.88 | |
| Operating Cash Flow | -19.52 | -13.34 | -18.07 | -15.76 | -5.27 | |
| Capital Expenditures | -0.01 | -0.02 | -0.04 | -0.1 | -0.25 | |
| Sale of Property, Plant & Equipment | - | - | - | - | 0 | |
| Cash Acquisitions | 0 | - | - | - | - | |
| Investing Cash Flow | -0 | -0.02 | -0.04 | -0.1 | -0.25 | |
| Issuance of Common Stock | 8.85 | 16.4 | 15.91 | 0.01 | 26.38 | |
| Other Financing Activities | - | - | - | - | -0.86 | |
| Financing Cash Flow | 31.52 | 16.4 | 15.91 | 0.01 | 25.52 | |
| Net Cash Flow | 12 | 3.04 | -2.2 | -15.86 | 20 | |
| Free Cash Flow | -19.52 | -13.36 | -18.11 | -15.86 | -5.52 | |
| Free Cash Flow Per Share | -28.31 | -1063.68 | - | - | - | |
| Cash Interest Paid | 0.01 | 0.02 | 0.03 | 0.04 | 0.02 | |
| Levered Free Cash Flow | -13.53 | -7.53 | -11.21 | -9.96 | -3.7 | |
| Unlevered Free Cash Flow | -13.53 | -7.51 | -11.17 | -9.94 | -3.64 | |
| Change in Working Capital | 0.02 | -0.35 | -1.08 | 1.31 | 0.43 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.